The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

Abstract

Fibroblast growth factor receptor 1 oncogene partner N-terminal like gene (FOPNL) rs72773978 polymorphism was identified as an adverse prognostic factor in multiple myeloma (MM). We aimed to investigate the associations of rs72773978 with clinical characteristics and treatment outcome in 373 Hungarian MM patients. In our cohort, FOPNL polymorphism showed differential prognostic effect that depended on the treatment applied. Among patients treated with non-proteasome inhibitor (PI)-based therapy, carriership of the minor allele was significantly associated with adverse overall survival (p=.022). In contrast, the adverse effect was overcome by the application of PI-containing treatment (p=.048). Multivariate analyses revealed the independent adverse effect of rs72773978 on survival in the non-PI-treated group (p=.045), but not in PI treatment (OS: p=.093). We confirmed the adverse prognostic effect of rs72773978 associated with non-PI-based treatment regimens. Our results point to the importance of genotypic prognostic information associated with complex clinical background MM.

Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction

“… German 665 CDCA7L rs4487645 [98] 163 HNF1B SLC30A8 rs7501939 rs13266634 [75] 2267 TERT TERC rs2242652 rs12696304 [76] 983 FBXO33 INTU BCL6 IL17RB rs8014839 rs4618330 rs1903216 rs4687753 [200] 8. Hungarian 373 FOPNL rs72773978 ( [77] 211 PSMB1 rs12717 (G/G genotype) [78] ) 9. French 602 FOXM1 - [79] 10.…”

“…Kiss et al. [77] aimed to derive the relation of FOPNL (fibroblast growth factor receptor 1 oncogene partner N-terminal like gene) SNP rs72773978 with the clinical outcomes in 373 Hungarian MM patients. The genotype distribution of SNP rs72773978 was TT: 2 (0.5%), AT: 43 (11.5%), AA: 328 (87.9%) and the allele frequency in MM patients was 6.3 ± 1.8%.…”